Treatment of patients with recurrent primary brain tumors with AZQ.

Published

Journal Article

We have evaluated the efficacy of intravenous 2,5-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone (diaziquone or AZQ, NSC-182986) in the treatment of recurrent primary anaplastic brain tumors. Three of 16 evaluable patients (18.8%) showed clinical and radiographic improvement that permitted discontinuation of corticosteroids, 4 patients (25%) showed either clinical or radiographic improvement and were considered partial responders, and 9 patients (56.2%) showed no effects after two courses of AZQ. The treatment was well tolerated, and hematologic toxicity was mild. Pharmacokinetic studies indicated rapid decay of the parent compound from plasma using two different infusion schedules. These results compare favorably with those obtained using the nitrosoureas or procarbazine as single agents.

Full Text

Duke Authors

Cited Authors

  • Schold, SC; Friedman, HS; Bjornsson, TD; Falletta, JM

Published Date

  • May 1, 1984

Published In

Volume / Issue

  • 34 / 5

Start / End Page

  • 615 - 619

PubMed ID

  • 6538653

Pubmed Central ID

  • 6538653

International Standard Serial Number (ISSN)

  • 0028-3878

Digital Object Identifier (DOI)

  • 10.1212/wnl.34.5.615

Language

  • eng

Conference Location

  • United States